Under construction – not a live service
Sign in
Taking peopleNo phase

Checks bypass graft openness in heart attack patients after surgery on two blood-thinner plans

Compares graft openness with aspirin alone versus aspirin plus ticagrelor in adults after bypass surgery.

Plain-language title generated from the registry record
Registry title: Coronary CT Angio Evaluating Graft Patency in ACS Patients Treated With DAPT or Single ASA After CABG (CoCAP)

Key facts

Where
Bergen and Trondheim, NorwaySee the 2 sites

Where in Norway

  • Department of Heart Disease, Haukeland University HospitalBergen, NorwayEnrolling by invitation
  • St. Olavs University HospitalTrondheim, NorwayNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University Hospital, Linkoeping
Trial code
NCT04783701
Record updated
19 December 2025
Original description
The purpose of this study is to compare the presence of graft patency in single aspirin vs dual anti platelet therapy (DAPT) treatment including ticagrelor in patients with acute coronary syndrome (ACS) treated with coronary artery bypass surgery (CABG). Follow up time is 12-36 months postoperatively and the patency will be evaluated with coronary computed tomography angiography (CCTA)Read full original descriptionShow less

Coronary CT Angio Evaluating Graft Patency in ACS Patients Treated With DAPT or Single ASA After CABG (CoCAP)

The purpose of this study is to compare the presence of graft patency in single aspirin vs dual anti platelet therapy (DAPT) treatment including ticagrelor in patients with acute coronary syndrome (ACS) treated with coronary artery bypass surgery (CABG). Follow up time is 12-36 months postoperatively and the patency will be evaluated with coronary computed tomography angiography (CCTA)

Inclusion: Previously included in TACSI-trial.

Exclusion: Previous severe allergic reaction (i.e. anaphylactic reaction) to iodine-based contrast agents; Highly irregular heart rhythm (i.e. atrial fibrillation); Chronic kidney disease with estimated glomerular filtration rate (eGFR) <45ml/min/1,73m2; Body weight >120 kg; Not able to communicate; Not willing to participate.

ClinicalTrials.gov NCT04783701